ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
From Tregs to tissue remodelling: FOXP3 and IL-35 in the inflammatory landscape of nasal polyps.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammatory nasal polyps (NPs) are a chronic condition of the nasal mucosa linked with prolonged airway obstruction, frequent infections, and immune dysregulation. While the exact mechanisms underlying NP development remain unknown, new research indicates that immune-regulatory pathways are essential. Forkhead box P3 (FOXP3) and Interleukin-35 (IL-35) have attracted much interest.
methodsIn this narrative review, we examine how regulatory T cells (Tregs) release the potent immunosuppressive cytokine IL-35, suppressing effector T cell responses and encouraging Treg proliferation. Studies have shown that IL-35 is essential for preserving immunological homeostasis. FOXP3, a crucial transcription factor necessary for the development and maintenance of developing and maintaining immunological tolerance, controls the development and activity of Tregs. The pathophysiology of NPs is also included in this review, along with pertinent immunological indicators linked to the advancement of the condition.
resultThe balance between inflammatory and regulatory responses is upset in NP patients due to dysregulation of IL-35 and FOXP3, exacerbating chronic inflammation. Studying how they interact offers novel insight into the pathophysiology of NP and identifies potential curative approaches, such as Treg regulation and IL-35 supplementation. Parallel to this, pharmacological treatments such as corticosteroids and biologics (such as dupilumab) aim to reduce type 2 inflammation.
conclusionFOXP3 and IL-35 play an important role in maintaining immunological homeostasis, and their dysregulation is associated with the persistent inflammation seen in NPs. Relying on these regulatory mechanisms may represent a promising therapeutic direction, although further experimental and clinical validation is required beyond existing anti-inflammatory therapies. Further investigation is necessary to confirm their clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.